PRINCETON, N.J., Oct. 19 /PRNewswire/ -- ProQuest Investments announced today that Steven B. Ratoff, former Senior Vice President and Chief Financial Officer of the Pharmaceutical Group at Bristol-Myers Squibb, has joined the firm as a venture partner. Prior to joining ProQuest, Mr. Ratoff served as Chairman and Interim Chief Executive Officer of Cima Labs, Inc. where he was instrumental in its sale to Cephalon Inc. for over $500 million. He has also served as President and Chief Executive Officer of MacroMed, Inc. Previously, Mr. Ratoff served as Executive Vice President and Chief Financial Officer of Brown-Forman Corporation, a public diversified manufacturer of consumer products.
“I have known and worked with Steve for many years and I have always been impressed by his superb strategic understanding of the biotech landscape and his outstanding operational competence,” said Jay Moorin, managing partner at ProQuest. “We are excited that Steve has agreed to join ProQuest and believe that his talents and skills will be an excellent complement to our team.”
“I am pleased to join such a talented and successful group of people,” said Mr. Ratoff. “ProQuest’s superior performance in its first two funds is truly impressive, and I look forward to applying my experience and knowledge of the therapeutic environment in support of ProQuest’s new third fund.”
About ProQuest
Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $350 million under management. The firm has nine deal professionals and two offices, its headquarters in Princeton, New Jersey and a second office in San Diego, California.
ProQuest invests in healthcare companies seeking financings ranging from seed to late-stage. The firm’s portfolio reflects the rich diversity of the healthcare industry and exemplifies its commitment to fostering the growth of exceptional businesses. In addition to its breadth of experience across many sectors of the healthcare industry, ProQuest has special expertise in therapeutics, where innovations in drug discovery technologies and molecular analysis are transforming an enormous unmet medical need. With a proven superior track record and over 30 investments in such diverse therapeutic categories as oncology, pain and infectious disease, ProQuest Investments seeks to build long term, mutually beneficial partnerships with outstanding entrepreneurs.
ProQuest Investments
CONTACT: Pat DeAngelis, CFO and Administrative Partner of ProQuestInvestments, +1-609-919-3567, patd@proquestvc.com
Web site: http://www.proquestvc.com/